The gene sequencing technology developer has been spun out of Harvard University with $23m in series A capital provided by investors including Eli Lilly.
Lilly Asia Ventures, a regional investment subsidiary of pharmaceutical firm Eli Lilly, supported a $23m series A round yesterday for US-based gene sequencing technology developer ReadCoor.
The oversubscribed round was led by healthcare-focused investment firm Decheng Capital, while Vivo Capital and angel investor Hansjörg Wyss also contributed.
ReadCoor was spun out of Harvard University’s Wyss Institute for Biologically Inspired Engineering yesterday by the institution’s tech transfer arm Office of Technology Development.
The company will commercialise the institute’s spatial gene sequencing…
